TickerGuard
Buy Day today: Neutral (58) Mixed market breadth · no major macro event
GYRE

Gyre Therapeutics Inc.

Healthcare · Biotechnology

7.40$ +3.4% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

Gyre Therapeutics Inc. (GYRE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 199 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet GYRE
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
10.0 117 122 121 125 125 130 153 159 166 162 199
5.1 57 63 54 55 65 68 91 99 102 92 122
2.2 34 30 16 16 12 15 36 40 37 38 43
2.2 34 37 25 25 27 30 54 60 52 50 75
1.2 17 17 20 21 29 23 25 27 37 27 28
1.2 4.3 4.9 5.6 6.4 6.3 7.9 8.9 8.9 10 11 11
1.7 1.7 1.7 1.7 1.7 1.7 5.1 5.0 4.8 6.2 4.6 4.5
6.4 103 33 28 27 27 25 23 22 24 25 34
1.8 20 19 16 15 20 19 17 16 18 20 29
– 0.2 0.1 0.7 0.7 0.7 0.8 0.6 0.6 0.6 0.8 1.4
0.2 0.4 0.3 0.3 0.3 0.1 0.1 0.1 0.6 0.1 0.3 1.2
3.5 -16 57 60 63 63 68 92 102 106 101 130
-415 -86 -78 -74 -73 -73 -71 -70 -67 -68 -78 -138
77 77 103 104 103 102 102 89 103 103 91 101

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?